Some tips to help get started:
There are 386 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.
386 trials meet filter criteria.
Sort by:
HealthScout AI summary: The trial involves participants aged 16 and older with advanced solid tumors and BRAF alterations, evaluating the safety and efficacy of PF-07799933, a brain-penetrant pan-mutant BRAF inhibitor, as a monotherapy and in combination with binimetinib and cetuximab.
ClinicalTrials.gov ID: NCT05355701
HealthScout AI summary: The trial enrolls patients with advanced stage IIIB/IIIC or IV NSCLC with high PD-L1 expression (≥50%) to compare the efficacy and safety of cemiplimab monotherapy versus its combination with BNT116, an investigational mRNA cancer vaccine targeting tumor-associated antigens.
ClinicalTrials.gov ID: NCT05557591
HealthScout AI summary: This trial enrolls adult patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion, uncommon, classical (Ex19del and L858R), and T790M drug-resistant mutations to evaluate the safety and efficacy of PLB1004, an irreversible EGFR tyrosine kinase inhibitor targeting these mutations while sparing wild-type EGFR.
ClinicalTrials.gov ID: NCT06046495
HealthScout AI summary: This trial involves adult patients with untreated, advanced non-small cell lung cancer and high PD-L1 expression, evaluating cemiplimab combined with novel antibodies targeting TIM3, CD73, or NKG2A to assess safety, efficacy, and treatment outcomes.
ClinicalTrials.gov ID: NCT06162572
HealthScout AI summary: This trial evaluates MDNA11, an IL-2 Superkine targeting the IL-2 beta receptor to enhance anti-tumor immunity, administered alone or with pembrolizumab, in adult patients with locally advanced or metastatic solid tumors. Eligible patients must have an ECOG performance status of 0 or 1 and adequate organ function.
ClinicalTrials.gov ID: NCT05086692
HealthScout AI summary: This study targets patients with stage IIIB-IV NSCLC who have progressed on previous anti-PD-1/PD-L1 therapy and platinum-based chemotherapy, testing JNJ-86974680, an A2a receptor antagonist, both alone and in combination with cetrelimab, a PD-1 inhibitor, and radiation therapy.
ClinicalTrials.gov ID: NCT06116786
HealthScout AI summary: The trial targets adult patients with advanced or metastatic EGFR-expressing carcinomas such as NSCLC, CRC, and TNBC, who have exhausted other treatment options, using the investigational bispecific antibody JANX008 designed to activate in the tumor environment by targeting EGFR and CD3.
ClinicalTrials.gov ID: NCT05783622
HealthScout AI summary: This trial evaluates the safety and efficacy of the combination of amivantamab and cetrelimab, a PD-1 inhibitor, in metastatic NSCLC patients who have progressed after standard treatment, with patients grouped by EGFR mutation status or PD-L1 expression.
ClinicalTrials.gov ID: NCT05908734
HealthScout AI summary: This trial includes adult patients with relapsed or refractory advanced solid tumors, such as non-small cell lung cancer, renal cell carcinoma, and head and neck squamous cell carcinoma, who have an ECOG performance status of 0 or 1. It evaluates the safety and efficacy of ABBV-303, a trispecific killer cell engager targeting c-Met, as monotherapy and in combination with budigalimab, a PD-1 inhibitor.
ClinicalTrials.gov ID: NCT06158958
HealthScout AI summary: This trial involves patients aged 18 or older with stage IV non-squamous NSCLC, comparing the investigational PD-1 targeting antibody ABP 234 to pembrolizumab, both combined with pemetrexed and either cisplatin or carboplatin chemotherapy. Participants must have measurable disease without prior advanced systemic treatment and meet specific biomarker and genetic criteria.
ClinicalTrials.gov ID: NCT06311721